iShares NASDAQ US Biotechnology UCITS ETF (SWX:BTEC)

Assets	444.88M
Expense Ratio	n/a
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+48.68%

Volume	67,914
Open	10.27
Previous Close	10.31
Day's Range	10.24 - 10.48
52-Week Low	6.86
52-Week High	10.83
Beta	n/a
Holdings	255
Inception Date	Oct 19, 2017

About BTEC

iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.

• Asset Class: Equity
• Category: Sector Equity Biotechnology
• Region: North America
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BTEC

Performance

BTEC had a total return of 48.68% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.75%.

Top 10 Holdings

44.03% of assets

Name	Symbol	Weight
Gilead Sciences, Inc.	GILD	8.38%
Vertex Pharmaceuticals Incorporated	VRTX	7.61%
Amgen Inc.	AMGN	7.31%
Regeneron Pharmaceuticals, Inc.	REGN	5.30%
Moderna, Inc.	MRNA	4.11%
Revolution Medicines, Inc.	RVMD	2.73%
Illumina, Inc.	ILMN	2.42%
Alnylam Pharmaceuticals, Inc.	ALNY	2.14%
Biogen Inc.	BIIB	2.13%
Roivant Sciences Ltd.	ROIV	1.92%

Data Sources: S&P Global Market Intelligence, Twelve Data, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error